What Is the ChondroFiller Injection?

If you are living with joint pain caused by cartilage wear or injury, the question most patients ask first is not about the science — it is whether there is a non-surgical option worth trying before considering an operation. The ChondroFiller injection is one such option.

ChondroFiller is a Class III CE-marked type I collagen hydrogel scaffold, manufactured by Meidrix Biomedicals in Germany and imported into the UK under prescription. When used as an injection, it is delivered as an ultrasound-guided outpatient procedure: a clinician injects the collagen-based gel directly into the joint, with no incisions and no removal of any tissue. Once placed, the gel self-sets in a few minutes and may settle over worn surfaces, adding a protective, cushioning layer.

Because ChondroFiller is collagen-based and acellular, it has biological potential — it may recruit the patient's own progenitor cells to support the joint environment — but it is best understood as a supportive, joint-preserving treatment rather than a guaranteed repair. It does not cure or reverse arthritis.

How It Compares with Other Injections and Treatments

Several injectable treatments are used for joint wear, and patients rightly want to understand the differences.

• Hyaluronic acid injections work primarily as lubricants, reducing friction to ease symptoms — they do not address the structure of worn cartilage.
• Platelet-rich plasma (PRP) uses growth factors from the patient's own blood to support the joint environment and may have anti-inflammatory effects.
• ChondroFiller is a structural collagen scaffold: it occupies the defect area and may provide a biological environment to support tissue, making it a different class of intervention from simple lubrication.

For patients with larger or more complex chondral defects — particularly in load-bearing joints such as the knee, hip, shoulder, or ankle — a keyhole surgical approach may be more appropriate. The Liquid Cartilage procedure is a separate, genuinely surgical protocol (arthroscopic, performed under anaesthetic) in which ChondroFiller is placed under direct vision and combined with biological adjuncts such as platelet-rich fibrin and, where indicated, the patient's own mesenchymal stem cells. It is important to distinguish this clearly: the ChondroFiller injection is non-surgical and outpatient-based, while Liquid Cartilage is a different, surgical pathway using the same scaffold material in a more intensive setting. Assessment determines which, if either, is right for you.

What to Expect Before, During, and After

Before the Procedure

A thorough clinical assessment comes first. This typically involves review of symptoms, imaging (usually MRI), and a discussion of the joint's condition and the patient's goals. Not every patient is suitable: advanced arthritis, active infection, certain inflammatory joint conditions, and some anatomical factors may mean the injection is not appropriate. Assessment is therefore not a formality — it directly determines the path forward.

On the Day

The injection is generally a straightforward outpatient procedure. Ultrasound guidance is used throughout to place the gel accurately within the joint. There are no cuts, no cartilage removal, and no general anaesthetic is required. The procedure is usually brief, and most patients are able to leave on the same day.

After the Injection

Because the ChondroFiller injection is non-surgical, recovery is typically simpler than after an operation. Many patients return to normal daily activities relatively quickly. Some temporary soreness around the joint is not unusual in the first few days. Clinicians usually advise a short period of reduced loading, followed by a graduated return to activity; specific advice will depend on the joint treated and the individual's circumstances. The gel requires time to integrate, and any benefit tends to emerge gradually over weeks to months rather than immediately.

Realistic Expectations and the Evidence Base

Published clinical series using ChondroFiller report improvements in pain and function scores in suitable patients, including work in trapeziometacarpal (thumb base) osteoarthritis. Results vary between individuals, and the response depends on factors including the size and grade of the cartilage defect, the joint involved, age, activity level, and adherence to post-procedure guidance.

It is important to approach the injection with calibrated expectations: it is a joint-preservation measure with biological potential, not a cure. Some patients report meaningful reductions in pain and improved ease of movement; others see more modest benefit. A careful, honest discussion at assessment stage is the best preparation.

Conclusion

The ChondroFiller injection offers a non-surgical, outpatient route to joint support for patients with cartilage wear who are not yet at the stage of requiring surgery — or who wish to explore alternatives to surgery. Like any treatment, its suitability depends on individual circumstances, and realistic expectations matter.

At the London Cartilage Clinic, a specialist assessment can clarify whether the ChondroFiller injection, the Liquid Cartilage surgical procedure, or another pathway is the most appropriate choice for your joint and your goals. If you would like to discuss your situation, an initial consultation is the natural starting point.

References

Corain M, Zanotti F, Giardini M, Gasperotti L, Invernizzi E, Biasi V, Lavagnolo U. The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage. 2023.